These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21124044)

  • 41. Salvage with erlotinib plus bevacizumab: not in NSCLC.
    Sculier JP; Meert AP; Berghmans T
    Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
    [No Abstract]   [Full Text] [Related]  

  • 42. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
    Byrne BJ; Garst J
    Curr Oncol Rep; 2005 Jul; 7(4):241-7. PubMed ID: 15946581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
    Xu F; Tian Y; Huang Y; Zhang LL; Guo ZZ; Huang JJ; Lin TY
    Chin J Cancer; 2011 Oct; 30(10):701-11. PubMed ID: 21959047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
    Dziadziuszko R; Jassem J
    Ann Oncol; 2012 Sep; 23 Suppl 10():x193-6. PubMed ID: 22987961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
    Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
    Nishino M; Cardarella S; Jackman DM; Ramaiya NH; Rabin MS; Hatabu H; Jänne PA; Johnson BE
    AJR Am J Roentgenol; 2013 Jul; 201(1):W64-71. PubMed ID: 23789698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erlotinib.
    Steins M; Thomas M; Geißler M
    Recent Results Cancer Res; 2018; 211():1-17. PubMed ID: 30069756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Erlotinib.
    Steins M; Thomas M; Geissler M
    Recent Results Cancer Res; 2010; 184():21-31. PubMed ID: 20072828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
    Shrimali RK; Correa PD; Rizwanullah M
    BMJ Case Rep; 2008; 2008():bcr0620080075. PubMed ID: 21716815
    [No Abstract]   [Full Text] [Related]  

  • 53. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
    Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
    Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
    [No Abstract]   [Full Text] [Related]  

  • 54. Erlotinib.
    Steins M; Thomas M; Geissler M
    Recent Results Cancer Res; 2014; 201():109-23. PubMed ID: 24756788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
    Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
    Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
    Fartoux L; Desbois-Mouthon C; Poupon R; Rosmorduc O
    Gastroenterol Clin Biol; 2006 Oct; 30(10):1133-5. PubMed ID: 17075466
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.